Safety and Potency of a High Cabergoline Dosage in Microprolactinomas

Summary

This will be a multicenter, prospective, randomized, open-label trial with women harboring microprolactinomas and treatment naïve. The sample will be added consecutively and randomized into 2 unblinded groups: the high dosage group will receive a high cabergoline (CAB) dose for a period of \~6 months vs the standard dosage group, which will use the lowest needed dose of CAB to achieve normoprolactinemia for 2 years. The primary outcome will be remission rate.

Timeline

Start

2026-03-04

Primary completion

2027-08-20

Completion

2029-12-20

Drugs

Indications